AbbVie Expands Oncology Capability at the Company’s Site in Ballytivnan, Sligo
SLIGO, January 16th, 2018 – AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced an expansion of its manufacturing facility in Sligo to support the growth of its Oncology pipeline.
The $139 million (€113.6 million) investment in new sterile manufacturing technology at the Ballytivnan site will help deliver promising treatments for cancers with significant unmet medical needs. The expansion will create approximately 100 new jobs over the course of 3 years in a variety of technical and manufacturing positions. The project is supported by the Government through IDA Ireland.
Welcoming the announcement by AbbVie, Minister for Business, Enterprise and Innovation, Heather Humphreys TD, said "The pharma industry is a jewel in the crown of Ireland's new high-tech industries, with huge levels of investment and quality jobs being created. Government is keen that dynamic pharma companies like AbbVie can expand their operations as they will broaden the reach of the industry here and generate new opportunities. This is a major investment which will bring 100 new quality jobs and it has the added benefit of being located in the North West Region, which builds on the government's commitment to regional development as part of the Action Plan for Jobs process. This expansion of its operation in Sligo is a great vote of confidence in what that region has to offer.”
“This investment demonstrates AbbVie’s commitment to Ireland, and the laser focus of our team in Sligo on making a remarkable impact on patients’ lives,” said Joe Kumor, Site Director, Ballytivnan. “We are proud to be recognised for our high performance over the years, and are excited to have been chosen to help accelerate AbbVie’s oncology pipeline.”
CEO of IDA Ireland, Martin Shanahan said: “The pharma sector is one of our fastest growing sectors and makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports. This expansion by AbbVie is great news. It builds on their more than 70-year commitment to Ireland and is a tremendous vote of confidence in the capability of the workforce in Sligo and the wider North West Region. Securing regional investments is a key part of IDA’s strategy. I wish the company continued success.”
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. It employs more than 600 people at five manufacturing and commercial sites across Ireland. The company’s commercial headquarters is based in Dublin as is a separate international manufacturing and engineering services center. AbbVie has two manufacturing plants in Sligo and one in Cork.
The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.